Following a comprehensive executive search process conducted by the Board of Directors, Frederick M. Lowery was selected and appointed as the successor CEO, successfully taking over leadership reins. This structured succession plan ensured smooth operational continuity, with the previous long-tenured chief executive stepping back while remaining active as Chairman.
Frederick M. Lowery holds the position of Chief Executive Officer at Henry Schein, guiding the enterprise's strategic growth initiatives, global distribution networks, and digital transformation.
Sales representatives and field account managers at Henry Schein earn a competitive total compensation package that typically combines a dependable base salary with performance-based commission structures, sales bonuses, and travel allowances.
Henry Schein competes against several major medical and dental supply distributors, with its primary large-scale competitor being Patterson Companies in the dental distribution space, alongside massive healthcare logistics titans like McKesson Corpor...
Global investment firm KKR holds a significant strategic equity stake of approximately 12 percent in Henry Schein, making it the largest non-index fund shareholder in the company.
Frederick M. Lowery serves as the Chief Executive Officer of Henry Schein, having officially assumed the top executive role. He succeeded long-standing chief executive Stanley M.
Financial equity research analysts generally evaluate Henry Schein as a stable, defensive investment within the healthcare distribution sector, appealing primarily to value-oriented and long-term institutional portfolios.
Henry Schein is headquartered in the United States, with its primary corporate offices located in Melville, New York.
Henry Schein operates primarily as a massive global distributor, aggregator, and solutions provider rather than a primary manufacturing conglomerate.
Henry Schein maintains its primary global corporate headquarters in Melville, New York, situated within Suffolk County on Long Island.
Financial equity research analysts generally evaluate Henry Schein (traded under the ticker HSIC) with a consensus "Hold" to moderate "Buy" rating, appealing primarily to value-oriented investors seeking stability in the defensive healthcare distribu...
Field service technicians, equipment repair specialists, and dental technology support personnel at Henry Schein typically earn competitive hourly wages or annual salaries that scale based on technical certifications, geographic region, and years of ...
Henry Schein is an independently managed, publicly traded corporation listed on the Nasdaq Global Select Market under the ticker symbol HSIC, meaning it is collectively owned by thousands of public shareholders and large institutional asset managemen...
Henry Schein supports a robust, multinational workforce numbering over 24,000 professional employees worldwide.
Henry Schein was originally founded as a modest retail pharmacy in Queens, New York, by Henry Schein alongside his wife Esther Schein.
Yes, Henry Schein distributes regular quarterly cash dividends to its shareholders as part of its overarching capital allocation strategy.
Henry Schein has a rich corporate history spanning over nine decades, having been originally founded in 1932 as a small retail pharmacy in Queens, New York, by Henry and Esther Schein.
Salaries across Henry Schein vary widely depending on the specific job role, department, geographic location, and level of professional experience, ranging from hourly wages for warehouse and customer service personnel to six-figure salaries for corp...
Over the course of its extensive corporate history, Henry Schein has completed numerous strategic acquisitions to expand its global footprint, including purchasing various dental and medical supply distributors, software developers, and specialized h...
The Chief Executive Officer of Henry Schein receives a comprehensive executive compensation package that features a base annual salary of $1,250,000, alongside performance-based cash bonuses targeting at least 150% of the base salary, and substantial...
Henry Schein has not announced or implemented widespread, large-scale structural layoffs affecting its core workforce.
Comparing McKesson and Henry Schein depends entirely on the specific sector of healthcare distribution being evaluated, as McKesson is a massive pharmaceutical wholesale titan serving hospitals and health systems on a colossal scale, whereas Henry Sc...
Henry Schein is widely regarded as a strong, stable employer and a reputable corporate enterprise, frequently praised for its commitment to ethical business practices, comprehensive employee benefits, and professional development opportunities.